Bluebird Boasts Nearly 140% Revenue Jump, Still Misses Target

Bluebird bio released its first-quarter 2024 business report on Thursday, touting a nearly 140% year-over-year increase in revenue amid the growing uptake of its three gene therapies.

The Massachusetts-based biotech revealed that it has so far initiated 15 patients on its gene therapies, one of whom started the recently approved sickle cell disease (SCD) treatment Lyfgenia just this month. The remaining 14 patients are receiving either Zynteglo, for pediatric beta-thalassemia, or Skysona, which is intended for cerebral adrenoleukodystrophy in boys.